Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARL | Q9H300 | 2/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8102600 | 0.79 | PARL (0.42) | PARLMGLLKCNN4ALOX12KMT2A | |
| SCHEMBL31099227 | 0.76 | KCNN4 (0.38) | PARLMGLLKCNN4ALOX12MAPT | |
| SCHEMBL3686239 | 0.76 | PARL (0.40) | PARLMGLLKCNN4ALOX12MAPT | |
| SCHEMBL7387232 | 0.75 | GAA (0.44) | PARLMGLLKCNN4ALOX12KMT2A | |
| SCHEMBL23619542 | 0.74 | MGLL (0.34) | MGLLMAPTKMT2AATM | |
| SCHEMBL356558 | 0.74 | CHRM3 (0.36) | PARLMGLLKCNN4MAPTKMT2A | |
| SCHEMBL21447572 | 0.72 | ME2 (0.41) | PARLMGLLALOX12MAPTKMT2A | |
| SCHEMBL12993062 | 0.71 | ESR1 (0.41) | PARLMGLLMAPTKMT2AATM | |
| SCHEMBL260599 | 0.71 | MGLL (0.34) | PARLMGLLKMT2AATM | |
| SCHEMBL2570463 | 0.70 | MGLL (0.33) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6566491-B2 | Used as integrin inhibitors, in particular for the prevention and treatment of circulatory diseases, thrombosis, heart infarct, coronary heart diseases, arteriosclerosis, angiogenic diseases and in tumor therapy. | MERCK PATENT GESELLSCHAFT (DE) | 2003-05-20 | — | — | US | disclosed |
| US-20020032306-A1 | CYCLOPEPTIDE DERIVATIVES | BIOMET DEUTSCHLAND GMBH (DE) | 2002-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032306-A1 | CYCLOPEPTIDE DERIVATIVES | CORO1C, CYCS, CORO1A | PARL 1081/4885MGLL 4862/4885KCNN4 2437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.